No way! But... [Design Issues]

posted by PharmCat  – Russia, 2019-12-07 00:46 (1158 d 05:14 ago) – Posting: # 20954
Views: 5,433

Hi all!

❝ Correct. If we would be allowed (pun!) to use a mixed-effects model. Patterson and Jones argued against this doubtful practice and the ethical implications of discarding data.


Really, there is no problem in mixed model approach to use all data if model constructed correctly. May be not all regulatory bodies can understand how it works - it is not rare situations when I get issue like "Give me ANOVA!!! I don't want to see your GLM or MIXED...", pfff... or "In guideline ***(any ancient as mammoth's excrement guideline) written ratio of geometric means - please just divide one to another and give me CI"... So here two answers - theoretically there is no problem to use all data, but regulatory authorities can bann you for it. (IMHO)

Complete thread:

UA Flag
Activity
 Admin contact
22,481 posts in 4,710 threads, 1,603 registered users;
19 visitors (0 registered, 19 guests [including 10 identified bots]).
Forum time: 06:01 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5